🟢 97/100

This product looks safe

  • Niacin: 300mg is 8.6× the Tolerable Upper Intake Level (35mg)
  • 36% of ingredients have research evidence
C Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Safety Alerts

⚠️ Niacin: 300mg is 8.6× the Tolerable Upper Intake Level (35mg)

Label Data

6 Capsule(s) Serving Size
30 Servings
Other Combinations Product Type
36% Evidence Coverage

Supplement Facts — Evidence Check

Calories
44 Calorie(s)
Fat
600 mg (0.3% DV)
Trans Fat & Saturated Fat
Sugar
Carbohydrates
Cholesterol
300 mg (1500% DV)
⚠️ Exceeds Tolerable Upper Intake Level by 8.6× (UL: 35 mg) 📚 193 studies (Tier A: 5, B: 63)
RDA 14mg This product: 300mg UL 35mg
CMO
600 mg
1800 mg
📊 Market median: 1000.0mg (1115 products) 📚 22 studies (Tier A: 0, B: 9)
This product: 1800mg
600 mg
📊 Market median: 600.0mg (79 products) 📚 24 studies (Tier A: 0, B: 6)
This product: 600mg
300 mg
📊 Market median: 450.0mg (254 products) 📚 240 studies (Tier A: 0, B: 100)
This product: 300mg

Other Ingredients

Maltodextrin Gelatin Magnesium Stearate

Label Claims — Verification

All Other
Structure/Function
All Other (100% of products) Structure/Function (89% of products) Nutrient (16% of products)

Target Groups

Adult (18 - 50 Years)

Product Information

📋 Directions for Use

Suggested Use Take 6 capsules daily, 3 in the morning and 3 in the evening with or without food.

⚠️ Warnings & Precautions

For maximum results: Avoid alcohol, chocolate, coffee & other caffeine-containing drinks while taking CMO Plus.

🧪 Formulation Notes

Made in USA

"Energy Food for Joints"

Controls pain & inflammation Improves joint mobility

All natural, anti-inflammatory, anti-arthritic joint support formula.

Product Details

UPC / SKU 7 13757 03500 2
DSLD Entry Date 2022-01-22
Product Type Other Combinations
Form Capsule
DSLD ID 259071
Data Updated 2026-04-11

Research Evidence

39 Research Sources
50 Avg Quality Score
20 Rct
9 Meta Analysis
4 Clinical Trial
3 Systematic Review
1 Regulatory Source
1 Openfda Safety
B Interventions for the management of temporomandibular joint osteoarthritis
Systematic Review The Cochrane database of systematic reviews 2012
B Glucosamine therapy for treating osteoarthritis
Meta Analysis The Cochrane database of systematic reviews 2005
B Chondroitin for osteoarthritis
Meta Analysis The Cochrane database of systematic reviews 2015
B Efficacy and safety of the combination of glucosamine and chondroitin for knee osteoarthritis: a systematic review and meta-analysis
Meta Analysis Archives of orthopaedic and trauma surgery 2023
B Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis
Rct The New England journal of medicine 2006
B Oral Glucosamine in the Treatment of Temporomandibular Joint Osteoarthritis: A Systematic Review
Systematic Review International journal of molecular sciences 2023
B Scientific Opinion on glucosamine and joint health
Regulatory Source EFSA Journal 2009
B Clinical Efficacy and Safety of Chondroitin Combined with Glucosamine in the Treatment of Knee Osteoarthritis: A Systematic Review and Meta-Analysis
Meta Analysis Computational and mathematical methods in medicine 2022
B Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib
Rct Annals of the rheumatic diseases 2016
B Effectiveness and safety of glucosamine and chondroitin for the treatment of osteoarthritis: a meta-analysis of randomized controlled trials
Meta Analysis Journal of orthopaedic surgery and research 2018
View all evidence for Glucosamine →

Compare Similar Products

View all Glucosamine products →